US-based Quintiles, a contract research organisation providing a range of clinical research services for biotech and pharmaceutical clients, has closed its phase-I facility in Hyderabad due to what it called regulatory hurdles.
The facility was set up in association with the Apollo Group. Hyderabad was the fifth such facility to be closed down, joining units in London, Kansas in US and Uppsala in Sweden.
“A couple of months ago, the board of directors of Quintiles’ joint venture with Apollo Hospitals Enterprise took a decision to close the phase-I unit in Hyderabad due to the challenging external business environment. The unit was closed on September 30, 2013,’’ Quintiles India MD Anil Raghavan told FE in an email response.
The phase-I unit in Hyderabad opened in January 2011 and Quintiles employed about 20 employees in Hyderabad. “All employees of the phase-I Hyderabad unit who opted to continue their careers with Quintiles were absorbed in our other businesses,” he said.
“The decision has not impacted the rest of our business in India or our early clinical development operations elsewhere in the world. We continue to operate our clinical pharmacology units in London and Overland Park, Kansas, as well as partner sites in the US, EU and Asia and are well-positioned to provide a full suite of early clinical development solutions to customers,” he said.